Current options to manage Waldenström's macroglobulinemia.

about

Past, Present, and Future of Rituximab-The World's First Oncology Monoclonal Antibody Therapy.

P2860

Q55283747-23335903-F223-4CD0-A01A-58736B9634ED

P2860

Current options to manage Waldenström's macroglobulinemia.

Item

http://www.wikidata.org/entity/Q39358109

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Current options to manage Waldenström's macroglobulinemia.

@en

Current options to manage Waldenström's macroglobulinemia.

@nl

type

Item

label

Current options to manage Waldenström's macroglobulinemia.

@en

Current options to manage Waldenström's macroglobulinemia.

@nl

prefLabel

Current options to manage Waldenström's macroglobulinemia.

@en

Current options to manage Waldenström's macroglobulinemia.

@nl

P1476

Current options to manage Waldenström's macroglobulinemia.

@en

P2093

Elisa Santambrogio

http://www.w3.org/2001/XMLSchema#string

Giulia Benevolo

http://www.w3.org/2001/XMLSchema#string

Maura Nicolosi

http://www.w3.org/2001/XMLSchema#string

P2860

Ibrutinib in previously treated Waldenström's macroglobulinemia.

Risk of second cancers in Waldenström macroglobulinemia

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines

Risk of lymphoproliferative disorders among first-degree relatives of lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia patients: a population-based study in Sweden

Allogeneic stem-cell transplantation in patients with Waldenström macroglobulinemia: report from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation

Prognostic model for disease-specific and overall mortality in newly diagnosed symptomatic patients with Waldenstrom macroglobulinaemia.

Lenalidomide and rituximab in Waldenstrom's macroglobulinemia.

Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia

Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström Macroglobulinemia.

P304

637-647

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/17474086.2017.1339596

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Umberto Vitolo

P577

2017-06-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28592170

http://www.w3.org/2001/XMLSchema#string

Current options to manage Waldenström's macroglobulinemia.

about

P2860

P2860

Current options to manage Waldenström's macroglobulinemia.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698